The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pathologic response to neoadjuvant sequenced, lymphatic-sparing SBRT plus pembrolizumab in HPV-negative head and neck squamous cell carcinoma.
 
Richard Bell
Consulting or Advisory Role - Adela Bio; Bright Peak Therapeutics; EMD Serono; Macrogenics; Merck; Regeneron
Research Funding - Bristol-Myers Squibb/Celgene (Inst); Merck (Inst)
 
Rom Leidner
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb/Celgene; CDR-Life; Merck; RAPT Therapeutics; Vir; Vir
Research Funding - Bristol-Myers Squibb (Inst); Incyte (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb/Celgene
Other Relationship - Incyte
 
Marka Crittenden
Consulting or Advisory Role - Genentech/Roche
Research Funding - Bristol-Myers Squibb (I); Bristol-Myers Squibb (Inst); MedImmune (Inst); Regeneron; VIR Biotechnology (I)
 
Kristina Young
Consulting or Advisory Role - Corbus Pharmaceuticals; Synthis Therapeutics
Research Funding - Bristol-Myers Squibb
 
Steven Seung
No Relationships to Disclose
 
Ashish Patel
Travel, Accommodations, Expenses - Johnson & Johnson/Janssen; KLS Martin
 
Hong Xiao
No Relationships to Disclose
 
Matthew Taylor
Honoraria - Bristol Myers Squibb Foundation; Exelixis; OncoSec; Regeneron
Consulting or Advisory Role - Bristol-Myers Squibb; Exelixis
Speakers' Bureau - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Merck (Inst); Moderna Therapeutics (Inst); Pfizer (Inst)
 
Robert Hermann
No Relationships to Disclose
 
Thomas Duhen
Patents, Royalties, Other Intellectual Property - Provisional Patent Application 63/197,780; US Patent 11572541
 
Brian Piening
Consulting or Advisory Role - Lilly
Research Funding - Illumina (Inst); Loxo/Lilly (Inst); Shimadzu (Inst)
Patents, Royalties, Other Intellectual Property - System and Method for Automatic Labeling of Pathology Images. Patent pending. Matlock, Srinivasa, Bifulco, Piening inventors. Institutions: Omics Data Automation and Providence (Inst)
 
Michael Gough
Research Funding - Bristol-Myers Squibb (Inst)
 
Bernard Fox
Employment - UbiVac (I)
Leadership - UbiVac
Stock and Other Ownership Interests - PrimeVax; Turnstone Bio; UbiVac
Honoraria - Calidi Biotherapeutics; Incyte; Merck; Pfizer
Consulting or Advisory Role - Bristol-Myers Squibb; Incyte; Turnstone Bio
Research Funding - Hamamatsu Photonics; Incyte; Shimadzu
Patents, Royalties, Other Intellectual Property - Patent around the DPV-001 cancer vaccine. This patent is owned by the Providence Health System and licensed to UbiVac
Travel, Accommodations, Expenses - Bristol-Myers Squibb/Celgene; Incyte; Merck
 
Douglas Hanes
Employment - Providence Health and Services
Research Funding - Illumina (Inst)
 
Ezra Cohen
No Relationships to Disclose
 
Andrew Sharabi
No Relationships to Disclose
 
Robert Saddawi-Konefka
No Relationships to Disclose
 
Liza Blumenfeld
No Relationships to Disclose
 
J. Silvio Gutkind
No Relationships to Disclose
 
Joseph Califano
No Relationships to Disclose
 
Providence
No Relationships to Disclose